share_log

T2 Biosystems | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lind Global Fund II LP(0.5%),Lind Global Partners II LLC(0.5%), etc.

SEC announcement ·  Feb 14 09:17
Summary by Futu AI
On December 31, 2023, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing was an amendment indicating changes in the ownership of the company's common stock. The reporting entities and individuals, collectively referred to as the Reporting Persons, include Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, a U.S. citizen. Each of the Reporting Persons has reported beneficial ownership of 20,370 warrants to purchase T2 Biosystems' common stock, which represents 0.5% of the company's class of securities. The warrants provide the Reporting Persons with sole voting and dispositive power over the shares they could acquire. The principal business office for all Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, also includes a certification that the securities were not acquired for the purpose of changing or influencing the control of T2 Biosystems and were not held in connection with any transaction having such purpose or effect.
On December 31, 2023, T2 Biosystems, Inc., a medical device company, was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission. The filing was an amendment indicating changes in the ownership of the company's common stock. The reporting entities and individuals, collectively referred to as the Reporting Persons, include Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton, a U.S. citizen. Each of the Reporting Persons has reported beneficial ownership of 20,370 warrants to purchase T2 Biosystems' common stock, which represents 0.5% of the company's class of securities. The warrants provide the Reporting Persons with sole voting and dispositive power over the shares they could acquire. The principal business office for all Reporting Persons is located at 444 Madison Ave, Floor 41, New York, NY 10022. The filing, dated February 13, 2024, also includes a certification that the securities were not acquired for the purpose of changing or influencing the control of T2 Biosystems and were not held in connection with any transaction having such purpose or effect.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.